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Immune responses to citrullinated peptides have been described in autoimmune
diseases like rheumatoid arthritis (RA) and multiple sclerosis (MS). We investigated the
post-translational modification (PTM), arginine to citrulline, in brain tissue of MS patients
and controls (C) by proteomics and subsequently the cellular immune response of
cerebrospinal fluid (CSF)-infiltrating T cells to citrullinated and unmodified peptides of
myelin basic protein (MBP). Using specifically adapted tissue extraction- and combined
data interpretation protocols we could establish a map of citrullinated proteins by
identifying more than 80 proteins with two or more citrullinated peptides in human
brain tissue. We report many of them for the first time. For the already described
citrullinated proteins MBP, GFAP, and vimentin, we could identify additional citrullinated
sites. The number of modified proteins in MS white matter was higher than control
tissue. Citrullinated peptides are considered neoepitopes that may trigger autoreactivity.
We used newly identified epitopes and previously reported immunodominant myelin
peptides in their citrullinated and non-citrullinated form to address the recognition of
CSF-infiltrating CD4+ T cells from 22MS patients by measuring proliferation and IFN-γ
secretion. We did not detect marked responses to citrullinated peptides, but slightly more
strongly to the non-modified version. Based on these data, we conclude that citrullination
does not appear to be an important activating factor of a T cell response, but could be
the consequence of an immune- or inflammatory response. Our approach allowed us
to perform a deep proteome analysis and opens new technical possibilities to analyze
complex PTM patterns on minute quantities of rare tissue samples.
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INTRODUCTION
Citrullination is one of more than 400 known PTMs in human
proteins. The enzyme, peptidylarginine deiminase (PADI), is
responsible for modifying the amino acid arginine to the amino
acid citrulline. PADI is part of an enzyme family with five known
members (1), and each of these shows a distinct tissue and
substrate specificity. The enzymatic reaction results in the loss
of a positive charge of the peptide fragment and a mass increase
by 1 Da. The process of deimination is considered irreversible
since no citrulline-iminase is known so far (2). Gudman and
colleagues described citrullination in the context of diseases and
reported and postulated an increase of citrullinated proteins in
all inflammatory diseases (3). The effects of citrullination on
protein function depend on the location of the protein and the
position of the amino acid arginine. Since it removes a positive
charge from arginine, it may loosen protein interactions and
render them more prone to denaturation and degradation (4, 5).
Citrullination plays a role in several physiological mechanisms
like skin keratinization, myelin formation/remyelination, gene
regulation and immune functions. In specialized cells like
neutrophils, histone hypercitrullination is an essential process
in the formation of highly decondensed chromatin structures
termed neutrophil extracellular traps (NETs), which enable
these cells to trap and kill bacteria. During the last 10 years,
great attention has been paid to citrullination because of its
role in inducing anti-citrullinated proteins/peptide antibodies
(ACPA) (6). Involvement of citrullination in various diseases
like rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis,
chronic obstructive pulmonary disease (COPD), and Alzheimer
has been reported (7). In RA, immune reactivity toward various
citrullinated self-proteins and self-peptides like fibrinogen,
vimentin, fibrin, collagen type II, α-enolase and its involvement
in the disease pathogenesis have been well-established (8).
In MS, a chronic inflammatory demyelinating autoimmune
disease of the central nervous system (CNS), the amount of
the citrullinated myelin sheath protein myelin basic protein
(MBP) is increased in white matter as compared to control
brains (9), although these findings remain controversial (10,
11). In MBP that has been purified from MS brain tissue,
citrullination of six of the nineteen arginines has been found.
Among the myelin components, MBP has been studied in
greatest detail due to its importance for inducing experimental
autoimmune encephalomyelitis (EAE), a rodent model for MS
(12). The identification of CD4+ T cells reactive against epitopes
of several myelin proteins has been a consistent finding (12).
We had previously described reactivity of peripheral blood T
cells against post-translational modifications of autoantigens,
specifically against citrullinated peptides, in MS patients
(13). These preliminary studies hinted at elevated T cell
reactivity against citrullinated MBP and indicated that T cells
specific for citrullinated epitopes could escape central immune
tolerance (13, 14).
In the last years the focus has shifted from peripheral
blood-derived T cells to those that are found within the CNS
compartment, i.e. in the brain and cerebrospinal fluid (CSF)
(15, 16), since CNS-infiltrating T cells are considered more likely
to be relevant than those from the peripheral blood due to their
infiltration of the target tissue. Besides MBP, few other proteins
including glial fibrillary acidic protein (GFAP), neurogranin,
and histone H3 have been described to be citrullinated in MS
brain (10, 17).
MATERIAL AND METHODS
Human Brain Tissue Preparation
Tissue Collection
The UK Multiple Sclerosis Tissue Bank (UK Multicenter
Research Ethics Committee, MREC/02/2/39 and KEK-ZH-
Nr. 2014-0243), funded by the Multiple Sclerosis Society of
Great Britain and Northern Ireland (registered charity 207495)
supplied all the tissue samples. Tissue samples from white- and
gray matter were isolated from 9 control and 15MS cases. Gray
matter samples were from 6 controls and 6MS cases, white
matter samples from 3 controls and 9MS cases. All brains have
been screened by a neuropathologist to confirm the diagnosis
of MS and to exclude other confounding pathologies (UK MS
Tissue Bank).
Immunohistochemistry
All tissues were analyzed by immunohistochemistry. In order
to differentiate between white and gray matter, we stained the
tissue with anti-myelin oligodendrocyte glycoprotein antibodies
(MOG) and Luxol fast blue (LFB) for myelin as well as anti-
HLA-DR for macrophages/microglia. Regions of gray matter,
white matter, as well as lesions with active inflammation,
areas of remyelination, and demyelinated lesions without active
inflammation, could be identified. For LFB staining, LN3
(anti-HLA-DR), and MOG cryostat sections (12µm) were
fixed for 10min in 4% para-formaldehyde (PFA). Endogenous
peroxidase was blocked with 0.6% hydrogen peroxide in PBS
or 80% methanol for MOG staining. MOG staining was further
delipidated in 100% methanol at −20◦C for 8min. Tissues
were blocked with blocking buffer 1% normal donkey serum
(NDS), 0.1% Triton, 0.05% Tween in PBS, LN3: 5% NDS, 1%
fish skin gelatin 0.3M glycine in PBS) and incubated with the
primary antibodies at 4◦C overnight. Secondary biotinylated
antibodies were applied for 2 h at room temperature followed by
the ABC complex reagent (Vector Labs, Burlingame, California,
USA) for 1 h. The color reaction was performed with 3-Amino-
9-ethylcarbazole (18). For some sections, counterstaining in
hematoxylin was applied for 1min followed by rinsing the slide
in running tap water. For citrulline staining fresh frozen tissue
sections were first air-dried for 20min. before fixing them in
methanol at −20◦C. Incubation of sections with PBS before and
blocking in PBS/10%BSA for 1 h at RT. Incubation with antibody
F95 was performed overnight at 4◦C. Secondary biotinylated
antibody was applied for 1 h at RT followed by the ABC
complex reagent (VectorLabs) for 1 h. The color reaction was
performed with “ImpactDAB” (VectorLabs) and counterstaining
with hematoxylin as described above. Antibodies: LN3 (Abcam,
ab190298, 1:250), anti-MOG (Clone Z12, 1:100), anti-citrulline
F95 (Millipore, Burlington, Massachusetts, USA). LFB staining
was done with cryostat sections (12µm), fixed for 10min in 4%
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PFA. Sections were washed in PBS (3 × 5min) and ddH2O (2
× 1min), then incubated in 50% ethanol (5min), 70% ethanol
(5min), 80% ethanol (5min), and 96% ethanol (5min). Sections
were incubated in 0.1% LFB solution for 20 h at 56◦C. Sections
were washed in ethanol and ddH2O and developed in lithium
carbonate (0.05% in ddH2O) for 15 s and 70% ethanol for 1min
at RT. After cresyl violet staining (4min, RT) sections were
differentiated in 96% ethanol (30 s), dehydrated in ethanol and
xylol and finally mounted with “Entellan” (Merck Millipore).
Protein Extraction Protocol
We analyzed gray and white matter tissue from post-mortem
human brains (control and MS patients) in order to establish
a spectral library and protein database of the main protein
constituents of the CNS. The characterization of the tissue
used for the analysis is illustrated in Figure 1A. An overview
of samples that were used in the analysis together with
medical records is listed in Supplementary Table 1. For
protein extraction, a barocycler (Barocycler 2320EXT, Pressure
BioSciences, Inc, South Easton, MA, USA) was used. Tissue
samples of the size of a needle-head (2–3mg) were put into
barocycler 150 µl micro tubes. The tubes were filled with 30 µl
of lysis buffer (8M urea and 0.1M ammonium-bicarbonate) and
complete protease inhibitor cocktail (Roche, Basel, Switzerland)
and closed with 150 µl microcaps. After pre-heating the
barocycler for 30min at 33◦C, run cycles were performed at 45
kpsi for 60 cycles and 1min each. Each cycle lasted 50 s at high
pressure and 10 s at ambient pressure.
Reduction and alkylation were carried out as follows: Mixing
of TCEP [tris (2-carboxyethyl) phosphine] 2.5mg and IAA
(iodoacetamide) 3.7mg in 50 µl of lysis buffer. A volume of 4.9
µl of this buffer was added to each tube, incubated at 25◦C in
a thermomixer while shaking at 1,000 rpm and protected from
light. By adding lysis buffer, the urea concentration was diluted
from 8 to 6M. Lys-C enzyme digestion was applied to an enzyme
to substrate ratio of 1:40. Lys-C (mass spectrometry grade,Wako,
Richmond, VA, USA 20 µg/µl) was dissolved in “Milli-Q-water”
to a final concentration 4 µg/µl. Digestion was performed in
barocycler with 20 kpsi for 45min. and cycles of 50 s duration
at high pressure and 10 s ambient pressure.
A further dilution of urea from 6 to 1.6M with 0.1M
ammonium-bicarbonate buffer was necessary to achieve trypsin
digestion conditions. Trypsin (sequencing grade modified,
Promega, Madison, WI, USA) was added to an enzyme to
substrate ratio 1:20. The digestion took place for 90min at 37◦C
in a barocycler at 20 kpsi and cycle periods of 50 s at high
pressure and 10 s at ambient pressure (19). Finally, the solution
was transferred to a 1.5ml Eppendorf tube. The volume was
adjusted to 1ml by adding a 0.1%TFA/3%ACN solution and the
reaction was stopped by adding 10% TFA and pH adjusted to a
value between pH 2 and 3. The peptides were desalted on solid
phase extraction columns (C18/Finisterre, Wicom, Heppenheim,
Germany) according to manufacturer protocol. The samples
were vacuum concentrated in a “SpeedVac” and the peptides re-
dissolved in 3% ACN/0.1% formic acid in a volume of 20–50
µl to a final concentration of 1 µg/µl. Peptide concentration
was measured with Nanodrop instrument (Nanodrop 1000,
FIGURE 1 | (A) Histopathological examination of control and MS tissue. To
identify normal as well as lesioned tissue, tissue blocks containing white as well
as gray matter tissue were stained for MOG, HLA-DR, and Luxol Fast-Blue.
White and gray Matter control tissue showed no sign of demyelination and
inflammation (A–C and J–L). Also, NAWM and NAGM did not show any signs
(Continued)
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FIGURE 1 | of demyelination or inflammation (D–F and M–O). However, MOG
as well as LFB staining clearly show demyelination in lesional areas (G and I).
Further, a strong HLA-DR staining was visible in lesion tissue (H). (B)
Citrullination pattern in WM and GM of MS brain (staining with anti-citrulline
antibody F95). Inserts showing detail view of corresponding tissue. (C) 2–3mg
of brain tissue was disrupted in barocycler and digested by Lys-C and trypsin.
All treatments were performed in barocycler instrument. Finally, peptides were
desalted and dried.
spectrophotometer (Thermo Scientific, Wilmington, DE, USA)
and a solution of a concentration of 0.5 µg/µl prepared.
Hydrophilic Interaction Liquid
Chromatography (HILIC)
Pools of peptide samples of control tissue (C), as well as the
MS tissues from gray and white matter were prepared (300
µg each) and separated using Hydrophilic Interaction Liquid
Chromatography (HILIC) (Agilent LC1200 equipped with a
column Polyamin II 250 × 3.0mm 120 Å, 5µm). The applied
gradient was formed of the two solvents: A: 75% ACN, 8mM
KH2PO4 and B: 5% ACN, 100mM KH2PO4 (pH4.0) for 60min.
Fractions of 1ml were collected in 27 tubes (detailed protocol
as Figure S2). To reduce the number of the samples to be
analyzed on the mass spectrometer the fractions were pooled
from two tubes. Before injection, samples were purified on
“Finisterre SPE” columns (Wicom International, Heppenheim,
Germany). Samples of 1ml were vacuum dried and dissolved
in an appropriate buffer, 3%ACN/0.1%TFA. In total 11 fractions
for each tissue sample (control and MS of gray and white
matter) were prepared. After another vacuum drying, peptides
were dissolved in 3%ACN/0.1%FA buffer. Concentrations were
measured with Nanodrop instrument and adjusted to 0.25µg/µl.
Reference peptides (iRT) were added (iRT, Biognosys, Schlieren,
Switzerland) to each sample.
Data-Dependent Acquisition (DDA) of the HILIC
Fractionated Samples
The HILIC fractionated samples, 44 in total, were run on
Easy-nLC 1000 linked to an Orbitrap Fusion instrument
(Thermo Fisher, Waltham, Massachusetts, USA) on a gradient
of 80min. Column material was ReproSil-Pur, C18, 120 Å,
AQ, 1.9µm (Dr. Maisch GmbH, Ammerbuch Germany) and
column dimensions ID 0.075 mm/length 150mm. Solvent A
0.1% formic acid in water and Solvent B 0.15 formic acid in
acetonitrile. 4 µl of the sample at a concentration of 0.25 µg/µl
was injected.
Peptide and Protein Identification of
HILIC Samples
Identification by “Mascot”
We converted “Raw” files converted into “mgf” (20) files
and analyzed them on MASCOT software with a human
UniProtKB/Swiss-Prot protein database (date: March 22, 2016
with 40,912 entries): Search parameters were 0.05 Da fragment
mass tolerance and 10 ppm precursor mass, minimal number
of peptides 2, and FDR (false discovery rate) of 0.1%, allowing
2 mis-cleavages on trypsin fragments. We set carbamidomethyl
at cysteine as a static modification and oxidation of methionine,
deamidation on arginine (R) (with or without neutral loss),
glutamine (Q) and asparagine (N) as variable modification.
To estimate FDRs separately for deamidated and all the other
proteins the mascot.dat files were converted to the bibliospec file
format (Skyline).
Peptide Identification With “Ursgal”
The universal python module combining bottom-up proteomics
tools for large-scale analysis (Ursgal) was used to perform
a search with multiple search engines (xtandem vengeance,
msgfplus_v9979 and MyriMatch 2 2 140) (21). Evaluation
and post-processing of the search results were performed
using percolator_2_08.We adjusted the do_it_all_folder_wide.py
“Ursgal” example script (https://ursgal.readthedocs.io/en/latest/
example_scripts.html#do-it-all-folder-wide) to our input data.
We set the variable and fixed modifications in the same as for
“Mascot.” For instrument settings, we used the Q-Exactive+
Ursgal profile. We used the “unified_percolator_validated.u_
merged_accepted.u_merged.csv” tables (PRIDE), generated by
“Ursgal” for further analysis.
Post-translational Modifications, Citrullination and
Local False Discovery Rate (FDR) Determination
For each peptide, we selected the best peptide-spectrum match
(PSM) according to the lowest PEP- (percolator) or Mascot Ion
score. We computed the peptide FDR using the target-decoy
approach (22) implemented in the R-package TargetDecoyFDR
prozor (https://github.com/protViz/TargetDecoyFDR; https://
github.com/protViz/prozor). The FDR was estimated separately
for the deamidated and citrullinated peptide sequences and all
other sequences. The FDR for deamidated and citrullinated
peptide sequences increased much faster than for all other
sequences (see Figure S1) resulting in a more demanding
cutoff score for those sequences. We deposited the mass
spectrometry proteomics data in the ProteomeXchange
Consortium via the PRIDE (23) partner repository with the
dataset identifier PXD008344.
Isolation, Expansion, and Proliferative
Testing of T Cells
Peripheral Blood Mononuclear Cell Isolation
Allogeneic peripheral blood mononuclear cells (PBMCs) where
isolated freshly from anonymized buffy coats obtained from
the Blood Bank of the University Hospital in Zurich. Buffy
coats were first diluted 1:1 in PBS, and later PBMCs extracted
using a Ficoll gradient. Irradiated (45 Gray) allogeneic PBMCs
were used during the freezing procedure of the CSF cells and
again during the expansion of CSF-infiltrating CD4+ T cells
where they functioned as feeder cells. Fresh blood was obtained
in EDTA-containing tubes from all patients, from whom CSF
samples were available. PBMCs were isolated from fresh blood
using Ficoll density gradient centrifugation (PAA, Pasching,
Austria) and cryopreserved in 90% FCS (Eurobio) and 10%
DMSO (Applichem, Darmstadt, Germany).
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Isolation and Expansion of CSF-Infiltrating CD4+
T Cells
Fresh bulk CSF-derived mononuclear cells from the 22
CIS/RRMS patients were mixed with 5 × 106 allogeneic
irradiated PBMCs, and CD4+ T cells were subsequently
positively selected with anti-CD4 magnetic beads according to
the manufacturer’s instructions (Miltenyi, Bergisch-Gladbach,
Germany). CD4+ cell fractions were seeded at 1,500 cells per
well in 96-well U-bottom microtiter plates together with 1.5 ×
105 allogeneic irradiated PBMCs, 1µg/ml of PHA-L (Remel,
Thermo Fisher, USA) and IL-2 supernatant, derived from the
IL-2t6 (myeloma cells IL-2t6, a human lT cell leukemia line;
kindly provided by Federica Sallusto, Institute for Research
in Biomedicine, Bellinzona). The cell culture was cultivated
in RPMI 1640 medium (Pan-Biotech, Aidenbach, Germany)
supplemented with 2mM glutamine (Pan-Biotech), 1% (vol/vol)
non-essential amino acids (Gibco), 1% (vol/vol) sodium pyruvate
(Gibco, Carlsbad, California, USA), 50µg/ml penicillin-
streptomycin (Corning, NY, USA), 0.00001% β-Mercaptoethanol
(Gibco) and 5% inactivated human AB positive serum (Blood
Bank Basel). Additional IL-2 was added every 4 days. Growing
wells were transferred to 48/24 well plates and finally to 75 cm3
cell culture flasks until cells were fully rested (20–25 days). Cells
were highly expanded in a single round of stimulation.
Peptide Stimulation
Peptides were synthesized by Peptides and Elephants GmbH
(Henningsdorf, Germany) and dissolved in DMSO at a stock
concentration of 5mM. The peptides and their sequences which
we used are listed in Supplementary Table 2. The response of
PHA-expanded CSF-infiltrating CD4+ T cells to citrullinated
or non-citrullinated myelin and the CEF (CMV, EBV, influenza
virus, tetanus toxoid) (Peptides and Elephants GmbH), peptide
pool was tested by seeding 6 × 104 of expanded CSF-
infiltrating CD4+ T cells and 2 × 105 irradiated autologous
PBMCs in quadruplicates per each condition of peptide
stimulation or in the absence of peptides. Stimulation with
anti-CD2/CD3/CD28 beads (Miltenyi) was used as additional
positive control.
Proliferation Assay
The above described peptide stimulations of bulk CD4+ T
cells from CSF of oligoclonal band (OCB) positive relapsing-
remitting (RRMS) patients were then used to test T cell
reactivity with autologous irradiated PBMCs as antigen-
presenting cells. Proliferation of T cells was measured by
3H-thymidine incorporation. At day 2, the cells were pulsed
with 1 µCi of methyl-3H-thymidine per well (Hartmann
Analytic, Braunschweig, Germany) and harvested after 16 h
onto a membrane (Filtermat A, GF/C, Perkin-Elmer, Waltham,
Massachusetts, USA) using a semi-automated harvester (Tomtec,
Hamden, Connecticut, USA). Incorporation was measured by β-
scintillation counting (Wallac 1450, Perkin-Elmer). Proliferative
responses were given as counts per min (cpm) and the
stimulatory index (SI) was calculated as follows: SI = Mean
(replicates cpm peptide)/Mean (replicates cpm without peptide).
Cytokine Measurement
After 48 h of incubation and before adding thymidine, 100
µl of cell culture supernatant were removed in order to
test the cytokine secretion. Here, CD4+ T cell reactivity
to peptides was analyzed in supernatants for IFN-γ
using an IFN-γ ELISA (Biolegend, San Diego, California,
USA) according to manufacturer’s instructions. Cytokine
production higher than 100 pg/ml was considered as a strong
positive response.
HLA Typing
Individuals were typed for HLA class I and -II alleles at
Histogenetics LLC, NY, USA. Isolation of DNA fromwhole blood
was performed with a standard DNA isolation protocol using a
Triton lysis buffer and Proteinase K treatment. Purified genomic
DNA with a final concentration of 15 ng/µl was used to type
for HLA class I (A∗ and B∗) and HLA class II (DRB1∗, DRB3∗,
DRB4∗, DRB5∗, DQA1∗, and DQB1∗) using high-resolution
HLA sequence-based typing (SBT). The patients’ information is
summarized in Supplementary Table 3.
Statistical Analysis
Pearson correlation analysis was performed between responses
obtained from proliferation assay (thymidine incorporation) and
cytokine secretion (IFN-γ) for MOG and CEF peptides.
RESULTS
Characterization of Brain Tissue
To identify the different tissue types, e.g. normal appearing white
matter (NAWM) or lesion tissue, sections from tissue blocks
were immunohistochemically stained and analyzed (Figure 1A).
Stainings were performed for MOG (A, D, G, J, M), and HLA-
DR (LN3; B, E, H, K, N), as a marker for microglia and
macrophages and luxol fast blue (C, F, I, L, O), as markers
for myelin and oligodendrocytes (Figure 1A). Figure 1 shows
representative staining for control- (C) and MS tissue. LFB and
anti-MOG antibody staining identified sites of demyelination
(Figures 1A:G,I). Staining with anti-HLA-DR antibody shows
inflammatory cells (Figure 1A:H). Based on the staining, tissue
types were defined and then cut for protein isolation. Tissue
was taken from normal appearing gray matter (NAGM), normal
appearing white matter (NAWM) as well as from active lesions
from the diseased tissue. From control tissue, parts of gray
(GMC)- and whitematter (WMC)were excised. Figure 1B shows
an immunohistochemistry staining of citrulline in a section
of MS brain to illustrate the distribution of citrullination. We
observed substantially higher citrullination staining in white
compared to gray matter tissue.
Identification of Specific
Post-translationally Modified Peptides and
Proteins in Pre-fractionated Brain
Tissue Samples
For proteomic analysis we decided to extract proteins from
the brain tissue by barocycler. This technique allows to
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extract proteins efficiently from small sample sizes. It has the
advantage of using a single test tube from tissue disruption
until the tryptic digestion, thereby reducing the introduction of
technical variations in the samples (Figure 1C). To be able to
achieve a higher resolution of the brain proteome we decided
to render the samples less complex and therefore easier to
analyze. We first separated our peptide digests by hydrophilic
interaction chromatography (HILIC), and then two fractions
were pooled and injected into liquid chromatography coupled
to a mass spectrometer (see illustration in Figure S2). The pre-
fractionation process allowed us to identify 10,343 proteins
in gray matter and 8,730 proteins in white matter tissue.
These numbers correspond to combined data from control
and MS patients (Figure 2). The higher number of proteins in
gray matter tissue is not surprising since gray matter tissue
is more densely packed with cells than white matter tissue.
Overall, 7,950 proteins were common in both groups, white and
gray matter. In gray matter 2,393 proteins could be uniquely
identified compared with 780 in white matter (Figure 2A).
Since we were interested in the fraction of proteins involved in
processes of inflammation and the immune system an analysis
with “STRING-DB” (https://string-db.org/) was performed. We
submitted the entire protein list that we had obtained from MS
white matter and control tissue. The MS white matter showed a
network of proteins involved in immune reactions, which were
completely absent in WM control. Control tissue showed an
enrichment of a protein network of the nervous system (data
not shown).
FIGURE 2 | Overall distribution of proteins identified in white and gray matter (control and MS combined). A total number 10,343 proteins was identified in gray matter
and 8,730 proteins in white matter with an overlap of 7,950 proteins in both tissues (A). A number of 780 proteins were uniquely attributed to white matter and 2,393
proteins to gray matter. (B) Shows all peptide counts in the different search engines from white matter tissue (representative for all tissues analyzed). (C) This graph
presents the percentage of tryptic peptide sequence coverage of the whole protein, MOG, CNP, Neurogranin, MBP, and GFAP and their identification in the four
tissues analyzed, gray matter control (GMC), gray matter MS (GMMS), white matter control (WMC), and white matter MS (WMMS).
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Identification of Myelin Sheath- and Other
CNS Proteins
An important first step for the comparison of different brain
tissue samples is to assure that the protein extraction steps
worked with equal efficiency for the different samples. For
that reason, we analyzed “representative proteins” from the
myelin sheath and considered their presence as quality control
for the extraction efficiency. For myelin proteins, myelin
basic protein (MBP), myelin oligodendrocyte protein (MOG),
myelin-associated glycoprotein (MAG), myelin proteolipid
protein (PLP), and 2′,3′-cyclic nucleotide 3′-phosphodiesterase
(CNPase), for astrocytes, glial fibrillary acidic protein (GFAP),
and neurogranin as neuronal marker, we identified a high
number of peptides covering a major part of the respective
protein sequences. Figure 2C shows the peptide coverage (in %)
of these proteins. For MBP the coverage is optimal with more
than 90%. The sequence coverage of MOG was between 30 and
40% and for CNPase around 80%. Peptide sequence coverage
of GFAP was more than 90% and for neurogranin more than
45%. These numbers indicate a comparable efficiency of peptide
extraction from the tissues analyzed.
Identification of “in vivo”
Citrullinated Proteins
Our main goal was to analyze as detailed as possible, which
proteins are citrullinated inMS- and control brain tissue and also
for the main regions of the brain, i.e., gray and white matter..
In Figure 2B, we show the identification of all peptides from
white matter from control and MS. The search with “Mascot no
NL” (without neutral loss) identified 57,339 peptides, “MascotNL”
(Mascot, with neutral loss) revealed 56,858 peptides and “Ursgal”
identified 65,776 peptides. The majority of peptides was common
to all three algorithms; 51,780 peptides. Unique to the individual
search engines were 674 peptides for “Mascot no NL,” 279
to “MascotNL” and 10,912 peptides for “Ursgal” (Figure 2B).
Similar distributions were observed for gray matter tissue (data
not shown).
We based the further analysis on combined identification
from the software searches in Mascot (no NL), Mascot (NL) and
“Ursgal.” For most of the following analysis, we used peptides,
which had been identified by at least 2 of the search engines
since not all of them could be identified with all three. The
distribution of all spectral peptide matches and citrullinated
spectral peptide matches and their corresponding proteins
numbers from the different tissues are illustrated in Figure 3
and Supplementary Data 1. The highest number of citrullinated
spectral matches peptides was found in WM tissue (Figure 3A).
The lower part of the panel labeled with NO_Citr., represents the
overall number of spectral matches from the four different tissues
and shows a higher number in GM tissue. Further, very similar
numbers were found for gray matter of controls andMS (179,299
and 172,620), and similarly also for white matter tissue (146,867
in controls and 145,040 inMS). In Figure 3A (Citr., upper part of
the panel ) the peptide spectral matches show a strong increase of
the citrullinated fraction in the white matter tissue of MS (1,612)
vs. control (1,013). In contrast, in gray matter tissue, the numbers
were slightly lower in MS tissue (470) compared to control (500).
With respect to overall peptide numbers, there is little
difference between MS and control tissue (lower panel). The
elevated numbers of citrullinated peptides in white matter
therefore indicate a specific enrichment ofmodified peptides. The
diagram in Figure 3B shows the number of citrullinated proteins.
Here we only show white matter proteins in control and MS.
From the 179 proteins in MS white matter (WMMS) and 145 in
control white matter (WMC), we found 36 citrullinated proteins
to be unique to white matter tissue and 70 unique to gray matter
with an overlap of 109 in both tissues. A more detailed analysis of
these citrullinated proteins (>80) is shown in Table 1 as a non-
exhaustive list. It represents a selection of citrullinated proteins,
for which we identified at least two citrullinated peptides.
We grouped the proteins into functional or cellular processes,
FIGURE 3 | (A) The number of spectrum matched peptide of citrullinated peptides in all tissues are shown in upper panel (Citr.). All peptide spectrum matches found
in all four types of tissue gray (GM) and white matter are shown (WM) in lower panel (NO_Citr.). (B) Number of citrullinated proteins that were identified in white matter
tissue. From the total amount of 179 proteins in MS tissue and 145 in controls 70 proteins were unique in MS tissue and 36 proteins in control tissue with an overlap
of 109 proteins in both tissues.
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TABLE 1 | List of proteins with at least two citrullinated peptides identified in classified in functional groups.
Myelin associated proteins Synapse
P02686-5 MBP_HUMAN Myelin basic protein
P20916|MAG_HUMAN Myelin-associated glycoprotein
P09543|CN37_HUMAN 2′,3′-cyclic-nucleotide 3′-phosphodiesterase
Q92597|NDRG1_HUMAN Protein NDRG1
Q8TAM6|ERMIN_HUMAN Ermin
Q13875|MOBP_HUMAN Myelin-associated oligodendrocyte
basic protein
Q92686|NEUG_HUMAN Neurogranin
P61764|STXB1_HUMAN Syntaxin-binding protein 1
Q8N3V7|SYNPO_HUMAN Synaptopodin
Q9C0H9|SRCN1_HUMAN SRC kinase signaling inhibitor 1
Q13424|SNTA1_HUMAN Alpha-1-syntrophin
Neuronal development Membrane trafficking
Q09666|AHNK_HUMAN Neuroblast differentiation-associated protein
AHNAK
O15075|DCLK1_HUMAN Serine/threonine-protein kinase DCLK1
P78324|SHPS1_HUMAN Tyrosine-protein phosphatase non-receptor
type substrate 1
Q16555|DPYL2_HUMAN Dihydropyrimidinase-related protein 2
Q14195|DPYL3_HUMAN Dihydropyrimidinase-related protein
3P21291|CSRP1_HUMAN Cysteine and glycine-rich protein 1
Q9NRW1|RAB6B_HUMAN Ras-related protein rab6B
P63027|VAMP2_HUMAN Vesicle-associated membrane protein 2
Chaperonine like activity
P02511|CRYAB_HUMAN Alpha-crystallin B chain
P07900|HS90A_HUMAN Heat shock protein HSP 90-alpha
O95817|BAG3_HUMAN BAG family molecular chaperone regulator 3
Neuronal skeleton RNA binding proteins
P10636|TAU_HUMAN Microtubule-associated protein tau
P07196|NFL_HUMAN Neurofilament light polypeptide
P12036|NFH_HUMAN Neurofilament heavy polypeptide
Q16352|AINX_HUMAN Alpha-internexin
P61978|HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K
P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1
P38159|AUXI_HUMAN RNA-binding motif protein, X chromosome
P23588|IF4B_HUMAN
Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein
P68104|EF1A1_HUMAN Elongation factor 1-alpha 1
P38159|RBMX_HUMAN RNA-binding motif protein, X chromosome
Astrocyte specific
P14136|GFAP_HUMAN Glial fibrillary acidic protein
Membrane signaling Histone
Q8N7J2|AMER2_HUMAN APC membrane recruitment protein 2
Q9NZH0|GPC5B_HUMAN G-protein coupled receptor family C group
5 member B
P62807|H2B1C_HUMAN Histone H2B type 1-C/E/F/G/I
Cytoskeleton Cell adhesion
Q13885|TBB2A_HUMAN Tubulin beta-2A chain
Q9UEY8|ADDG_HUMAN Gamma-adducin
P04350|TBB4A_HUMAN Tubulin beta-4A chain
P07437|TBB5_HUMAN Tubulin beta chain
Q9BQE3|TBA1C_HUMAN Tubulin alpha
Q71U36|TBA1A_HUMAN Tubulin alpha-1A
P46821|MAP1B_HUMAN Microtubule-associated protein
P11137|MTAP2_HUMAN Microtubule-associated protein
P60709|ACTB_HUMAN Actin, cytoplasmic 1
O94811|TPPP_HUMAN Tubulin polymerization-promoting protein
Q9BW30|TPPP3_HUMAN Tubulin polymerization-promoting protein
family member 3
P35611|ADDA_HUMAN Alpha-adducin
Q8N7J2|AMER2_HUMAN APC membrane recruitment protein 2
Q14847|LASP1_HUMAN LIM and SH3 domain protein 1
P06396|GELS_HUMAN Gelsolin
O01082|SPTB2_HUMAN Spectrin beta chain, non-erythrocytic 1
Q96PY5|FMNL2_HUMAN Formin-like protein 2
O43491|E41L2_HUMAN Band 4.1-like protein 2
O75122|CLAP2_HUMAN CLIP-associating protein 2
O75781|PALM_HUMAN Paralemmin-1
Q13813|SPTN1_HUMAN Spectrin alpha chain, non-erythrocytic 1
Q92614|MY18A_HUMAN Unconventional myosin-XVIIIa
Q16181|SEPT7_HUMAN Septin
Q15149|PLEC_HUMAN Plectin
Q14244|MAP7_HUMAN Ensconsin
Q9H3Q1|BORG4_HUMAN Cdc42 effector protein 4
Q07157|ZO1_HUMAN Tight junction protein ZO-1
Q9UDY2|ZO2_HUMAN Tight junction protein ZO-2
P26232|CTNA2_HUMAN Catenin alpha-2
Cell matrix interaction
Q14CZ8|HECAM_HUMAN Hepatocyte cell adhesion molecule
P78333|GPC5_HUMAN Glypican-5
Endocytosis
O75061|AUXI_HUMAN Putative tyrosine-protein phosphatase auxilin
O00193|SMAP_HUMAN Small acidic protein
Q9UBC2|EP15R_HUMAN Epidermal growth factor receptor substrate 15-like 1
Phosphatase inhibitor
Q96A00|PP14A_HUMAN Protein phosphatase 1 regulatory subunit 14A
Endoplasmic Reticulum
Q9UNZ2|NSF1C_HUMAN NSFL1 cofactor p47
Energy transduction
P12277|KCRB_HUMAN Creatine kinase B-type
P11216|PYGB_HUMAN Glycogen phosphorylase, brain form
(Continued)
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TABLE 1 | Continued
Q765P7|MTSSL_HUMAN MTSS1-likEprotein
P35241|RADI_HUMAN Radixin
Q9H9H5|MA6D1_HUMAN MAP6 domain-containing protein 1
Immune response
P43243|MATR3_HUMAN Matrin-3
P17858|PFKAL_HUMAN ATP-dependent 6-phosphofructokinaseNuclear membrane
P20700|LMNB1_HUMAN Lamin-B1
P02545|LMNA_HUMAN Prelamin-A/C
Q9H910|HN1L_HUMAN Hematological and neurological expressed
1-like protein
FIGURE 4 | Continued
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FIGURE 4 | (A) A StringDB representation of citrullinated proteins in MS (red) and controls (blue) tissue. Edge settings is high-confidence (minimum required
interaction score 0.700). Overlapping in both tissues are depicted in pink. (B) Altman Bland plot. Vertical axis shows the mean number of peptide spectrum matches
against citrullinated sequences in controls and MS donor for white matter. The vertical axis shows the differences in PSM between MS and controls. Highlighted in
Red are proteins discussed in the text. (C) This figure shows a list of other most citrullinated proteins. Overall numbers of tissue distributions are shown: Vimentin,
2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CN37), ermin (juxtanodin), dihydropyrimidinase-related protein 2 (DPYL2 or crmp2) and neurofilament medium
polypeptide (NFM). Most of the proteins show a higher range of citrullinated peptides in white matter of diseased tissue. Only NFM is citrullinated in a similar manner in
all tissues analyzed. (D) Distribution of citrullinated sites in one of the major citrullinated proteins in brain tissue MBP. The bars represent the numbers of modified
arginine sites in corresponding tissue of control and MS cases. Peptide spectral matches, which were used for quantification of the modified sites are shown as
supplements. MBP sequence (P02686-5) with modified arginine found in our analysis. 16 out of 19 arginine sites were found to be citrullinated in control and diseased
brain (MS) tissue. Sites R6, R10, and R55 were never found to be altered. We never found R171 to be citrullinated in gray matter tissue. (E) Distribution of citrullinated
sites in another major citrullinated protein in brain tissue GFAP. The bars represent the numbers of modified arginine sites in corresponding tissue of control and MS
cases. Peptide spectral matches, which were used for quantification of the modified sites are shown as supplements.
such as myelin-associated proteins, neuronal development,
neuronal skeleton, astrocytes, synapse, energy transduction,
membrane trafficking, cytoskeleton in general immune response
and anti-apoptotic activity. The distribution and the possible
interactions of the citrullinated proteins are illustrated in
Figure 4A in the protein interaction network generated by String
(24). Figure 4B shows the differences regarding citrullination as
numbers of peptide-spectrummatches betweenMS and controls.
For GFAP and MBP much higher numbers of spectra matching
citrullinated sequences were detected in MS than in controls.
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Other proteins worth mentioning are vimentin (VIME) and
CNPase (CN37). Proteins with strong citrullination pattern, i.e.
more than three citrullination sites, are represented in Figure 4C.
Vimentin, an intermediate filament protein, is important for
maintaining the structure of a cell. It had already been described
in AD (25) and is one of the most citrullinated proteins besides
MBP and GFAP in WMMS. We found an increased number of
modifications in both tissues of MS in comparison to controls.
CNPase is an oligodendrocyte-specific protein and one of the
most abundant proteins in CNS myelin. Its function remains
unknown. CN37 has been described as an autoantigen inMS (26)
and had been identified to be citrullinated in a mouse model (27).
We identified a higher number of citrullinated CN37 peptides
in human brain white matter tissue as compared to published
data (28). In gray matter, we noticed slightly more citrullinated
spectral matches in controls.
We describe for the first time citrullinated sites of members
of neurofilament protein family (NFL, NFM and NFH), DPYL2
(dihydropyrimidase-related protein 2, CRMP2), a protein
involved in neuronal development and polarity (29), and human
ermin, a protein playing a role in myelin development and
maintenance and stability of myelin sheath (30). Among the
three members of neurofilament proteins, there was no difference
with regard to citrullination across tissues and donors. We show
neurofilament medium chain (NFM) as a representative member
of that group.
The protein DPYL2 showed a particularly increased number
of modified peptides in WMMS tissue and a slight increase
in GMC.
The protein with the highest number of modified/citrullinated
peptides in all tissues was MBP followed by GFAP, which
will be described in more detail. The analysis of total spectral
counts showed that overall comparable amounts of spectra were
observed in control and MS tissue of gray matter, and in white
matter citrullinated spectral counts were strongly increased in
MS white matter whereas the number of citrullinated spectral
counts in gray matter was slightly reduced in MS tissue.
Citrullination and Other Modifications of
Myelin Basic Protein
We examined in more detail MBP as one of the import
proteins of the myelin sheath and due to its role as
target in autoimmune responses. MBP can undergo post-
translational modifications at various sites. Those modifications
are phosphorylation, methylation, oxidation, citrullination and
deamidation/isomerization. So far, very little is known about the
implication of these modifications in disease processes in MS
(31–33). In our study, we found 16 out of the 19 arginine sites to
be modified into citrulline (Figure 4D). Earlier studies described
6–9 arginine sites in MBP to be citrullinated in MS “in vivo” (32,
34). In these studies, MBP was purified prior to analysis, while we
analyzed whole tissue extracts from histologically characterized
sites. We observed various modifications on different amino
acids and will describe some of them in more detail. The
peptide MBP (77–92) “(K)SHGRTQDENPVVHFFK(N)” was
modified at multiple sites. Modifications occurred at asparagine
(N-85), arginine (R-80), and glutamine (Q-82); DENP, HGRT,
and RTQD. The peptide “(K)GVDAQGTLS(K)” (144–154) was
deamidated at DAQG (Q-148). We mention these deamidations
since these modifications have been analyzed previously in MS
patients and healthy donors (32, 35). These two reports show
that deamidation of the latter peptide (MBP 144–154) can
increase with age in MS patients and others in animals (32).
The deamidation of glutamine (Q) in the peptide sequence (82–
90) (QDENP) has been shown to block its degradation by the
protease cathepsin-D in Alzheimer’s Disease (36). In our analysis,
we found that 15 (16) identified citrullination sites were present
in control as well as in MS tissue, in gray—and in white matter. A
16th position could only be found in WMMS.
To see if there is any specific citrullination pattern of
MBP, we counted the number of peptides and the respective
citrullinated sites and plotted them over the whole protein
sequence (Figure 4D). Citrullination is not unique to MS tissue
and neither in GM nor WM tissue. Some citrullinated sites were
strongly over-represented in MS tissue, i.e., R26, R32, R34, R44,
R50, R66, and R98. In GM, only the sites R26 and R44 were
slightly more citrullinated in MS tissue compared to control.
The situation for the structural protein GFAP looked similar.
GFAP protein was found to be much more modified in
WM as compared to GM from MS tissue. Highly modified
sites among others were positions R12, R36, R41, R49, and
R390 and R416. Similar to MBP, GM tissue generally shows
a much lower state of citrullination and a relatively higher
rate in control tissue (Figure 4E; Supplementary Data 1). Since
citrullination depends on the activity of PADI, we looked for
the presence of PADI in the tissues. We could identify a
substantial number of peptides from the isoform PADI2 (between
18 and 20 peptides across all tissue representing between 32
and 45% of protein sequence, data not shown). No peptide of
PADI4, the other isoform described to be present in CNS (17),
could be found.
Immunological Reactivity Against
Citrullinated MBP Peptides
In order to find out if the citrullinated MBP peptides are targeted
by the immune system we examined CSF-infiltrating CD4+ T
cells from 22MS patients. We analyzed CSF-derived T cells
under the assumption that they are more likely to be biologically
relevant in MS than peripheral blood lymphocytes, since the T
cells have already infiltrated the CNS compartment. For that
purpose, CD4T cells were freshly isolated and expanded as
described (16) from CSF of 19 relapsing remitting MS, 2 primary
progressive MS and 1 clinically isolated syndrome patients
(Table 2 and Supplementary Table 3), and, subsequently tested
in quadruplicates for eight newly identified citrullinated MBP
peptides together with the non-modified peptides. Furthermore,
seven immunodominant myelin peptides were examined, and,
only for MBP, the most abundant citrullinated epitopes were
included in the assay (Supplementary Table 2). Proliferation and
IFN-γ production were used as functional readouts. Positive
responses to CEF, a peptide pool of CMV, EBV, influenza virus
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TABLE 2 | Main clinical information and CSF findings of MS patients.
MS patients (22 subjects)
Age (y) 37.3 ± 12.6 (17–58)
Gender (F/M) 15/7
Disease duration (y) 1.6 ± 4.4
Patients with disease duration < 12 months (%) 16 (73%)
Time from last relapse (m) 1.3 ± 2.2 (0–8)
Patients with MRI-LP delay < 1 month (%) 20 (91%)
MRI active patients (%) 11 (50%)
CSF-restricted IgGOCB 21 (95.5%)
Patients with IgG Index > 0.70 (%) 15 (68.2%)
Blood-brain barrier damage (%) 5 (22.7%)
CSF cell count (/µL) 7 ± 3
Disease duration was defined as the time-span between disease onset and lumbar
puncture (median value and range are reported). The “time from last relapse” value did not
include Primary Progressive MS data. As indicated by the narrow interval between MRI
and LP (MRI-LP delay), the great majority of MS patients received MRI the day before
LP. Blood Brain Barrier (BBB) damage was considered when the albumin quotient (QAlb)
exceeded the normal value for patient’s age (i.e., age/15 + 4). y, years; m, months.
and tetanus toxoid, and global T cell stimulation by anti-
CD2/CD3/CD28 beads were tested in parallel as positive controls.
Four patients (1444ME, 1479CR, 1453AN, 1489HE) showed
responses to CEF peptides with a stimulation index (SI) > 2, but
we did not observe specific recognition of citrullinated- and non-
citrullinated MBP peptides in proliferation assays (Figure 5A).
When we analyzed the IFN-γ secretion in the culture supernatant
of the same wells tested for proliferation, we did also not
find strong IFN-γ release upon exposure to citrullinated MBP
peptides, but weak responses in only a few patients and one
of the four replicate wells (Figure 5B). On the other hand, in
two patients (1673UR, 1283RO), IFN-γ secretion (∼50 pg/ml)
in response to several non-modified epitopes of the MBP protein
was seen (Figure 5B). Given these results, we conclude that the
non-modified peptides are more frequently recognized by CSF-
infiltrating CD4+ T cells compared to the citrullinated version
and that the reactivity to the latter is overall very low.
Global T cell stimulation resulted in clear responses in all
donors, whereas responses to CEF peptides were less frequent.
The reactivity observed in proliferation assays to CEF positive
control peptides was partially paralleled by IFN-γ release. Only
two out of the four patients (1453AN, 1489HE) responding
in thymidine incorporation assay, produced also IFN-γ at
high concentrations (∼400 pg/ml). However, additional patients
(1460ML, 1188ZA) responded to these antigens (Figure 5B).
When examining other immunodominant myelin peptides
(9, 37) we observed in most cases IFN-γ secretion. Several
patients reacted clearly to MOG2 (35–55) peptide (Figure 6A).
1444ME showed proliferation with a stimulatory index (SI) of
5 (data not shown), 1673UR, 1283RO, and 1560RO release
of IFN-γ (∼300 pg/ml). 1283RO responded with high IFN-
γ release to other non-citrullinated, immunodominant MBP
peptides (Figure 6A) in comparison to the citrullinated version
(Figure 6A). These data show that bulk CSF-infiltrating CD4+
T cells of MS patients are able to recognize at the same
time different epitopes of the same protein but also different
antigens. No significant association between peptide recognition
and the MS risk-associated HLA-DRB1 alleles, i.e., DRB1∗15:01,
DRB1∗13:01, and DRB1∗03:01, was observed (reported below
the graphs).
Since we observed substantial differences in the results
obtained from the two response readouts, i.e., thymidine
incorporation vs. IFN-γ release, we wanted to assess a correlation
between the two measures and applied Pearson Correlation
testing on CEF- and MOG peptides responses. We observed
(Figure 6B) a strong positive correlation (r = 0.7671) for CEF
peptides (p < 0.0001), but only a weak correlation for MOG (r =
0.1857), where the majority of responses were detected by ELISA.
These results show that IFN-γ secretion appeared to be more
sensitive than proliferation as readout.
DISCUSSION
We investigated the composition of citrullinated proteins from
human post-mortem brain tissue. Tissues were characterized by
immunohistochemistry staining with antibodies against MOG
and HLA-DR and LFB. These markers allowed to distinguish
tissue with lesions from NAWM. Some of the tissue sections
showed increased staining for citrullination in white matter
compared to gray matter tissue, an observation that correlated
well with our proteomic findings. Based on mass-spectrometry,
we could identify a high number of citrullinated proteins,
which far exceeded the numbers already published in human
CNS (9, 38). By establishing a “spectral peptide library”
from different disease-relevant brain tissues and controls, we
provide a basis for further, more extensive investigation of
the MS brain proteome. We combined an optimized protein
extraction technique based on PCT (pressure cycle technology)
with chromatographic pre-fractionation, HILIC, to obtain high
proteome coverage. We searched our mass spectrometry data
with various search engines to distinguish post-translational
modifications and identify citrullination. The difficulty of
correctly identifying minute mass changes, i.e., an increase
of 1 Da per citrullinated site, made it necessary to apply
complementary bioinformatics approaches to validate the results,
since another post-translational modification, deamidation,
which also increases the molecular mass by 1 Da, occurs in aging
tissue on asparagine (N) and glutamine (Q) and can be a source
of misinterpretation. Therefore, we used different algorithms
to interpret the spectra and features, which are inherent of
citrullinated proteins, i.e., resistance to tryptic digestion and the
neutral loss of 43 Da inside the mass spectrometer instrument
(39). Most of the citrullinated proteins we identified, as well
as new citrullinated sites of MBP had not been described in
MS tissue before. So far, citrullinated myelin proteins had been
analyzed from excised bands (SDS-PAGE) or after “in vitro”
citrullination, but not from entire tissue. We used two software
“Mascot” and “Ursgal” to identify citrullination. Depending on
the search parameters and software the number of identified
peptides varied as illustrated in Figure 2B. We could not
detect any of the N-terminal arginines to be citrullinated. This
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FIGURE 5 | Recognition of citrullinated vs. non-citrullinated MBP in CSF-infiltrating T helper cells of MS patients. (A,B) Reactivity of CSF-infiltrating CD4+ T cells from
untreated MS patients to citrullinated MBP (left) and non-citrullinated MBP peptides (right), using irradiated autologous PBMCs as antigen-presenting cells. Each
square represents one well. MS risk-associated HLA-DRB1 alleles are reported for each individual under the respective graph. (A) Proliferative responses to MBP
peptides, CEF peptides or anti-CD2/CD3/CD28 stimulation as positive control are given as stimulatory index (SI). The strength of the response is depicted by color
coding. A SI > 2 is considered as positive response. (B) Responses detected by IFN-γ secretion against to MBP peptides or CEF peptides in the same wells that
have been tested in the proliferation assay. The IFN-γ concentration in culture supernatants is depicted as pg/ml.
phenomenon had been reported earlier concluding that “N-
termini” are less prone to be citrullinated (38).
Citrullination facilitates enzymatic degradation of MBP but
in the situation of increased citrullination, especially of myelin
proteins, scavenger cells like macrophages might have difficulties
coping with a high amount of proteins to degrade. It could also
be that the presence/absence or activity of specific proteases like
cathepsins play a role.
Citrullinated residues can be considered “neo-antigens” since
they are not necessarily available during thymic selection of T
cells and since citrulline is not one of the naturally occurring
L-amino acids. Hence, T cells with high avidity T cell receptors
against citrullinated peptides, which are presented via MHCII
molecules, might escape negative selection in the thymus and
target citrullinated peptides in the CNS. Earlier data from
testing PBMCs and PBMC-derived T cell lines with proteolytic
fragments (13) and 6 modified arginines in MBP, which had
been known at that time (40), had indicated increased reactivity
against citrullinated MBP epitopes. However, these data were
preliminary due to incomplete knowledge of the citrullinated
sites and other limitations. After analyzing in detail the possible
citrullination sites in the present study, we wanted to expand the
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FIGURE 6 | Recognition of citrullinated vs. non-citrullinated immunodominant myelin peptides and correlation of readouts. (A) Reactivity of CSF-infiltrating CD4+ T
cells to immunodominant MBP citrullinated (up) and immunodominant myelin (down) peptides, using irradiated autologous PBMCs as antigen-presenting cells. Each
square represents one well. MS risk-associated HLA-DRB1 alleles are reported for each individual under the respective graph. Responses detected by IFN-γ secretion
in culture supernatants are depicted as pg/ml. (B) Pearson correlation analysis is performed for MOG and CEF peptides. Data obtained from ELISA and proliferation
assay are compared and each dot represents one well-tested. Significant strong correlation between the readouts is detected for CEF (p < 0.0001) while for MOG a
mild correlation is shown (p = 0.0136).
prior data by testing bulk CSF-infiltrating CD4+ T cells, i.e., from
the CNS compartment, against MBP peptides containing the
newly identified citrullinated sites and against control antigens.
These studies aimed at the question if T cell reactivity against
citrullinated epitopes of MBP is increased in MS as it has been
described in a subset of rheumatoid arthritis patient for antibody
reactivity against citrullinated peptides (41), and, if not generally
increased in MS, whether it is found in a subset of patients. Our
findings show that there is very little reactivity again citrullinated
MBP epitopes and that it is thus unlikely to play a role in the
autoimmune response inMS.When comparing the present study
with previous data (12, 13), the testing of CSF-infiltrating T
cells, which are more likely to be disease-relevant than PBMC-
derived T cells, and of a larger number of individuals are the
most important differences. The fact that we observed reactivity
against MOG- and CEF peptides in a number of individuals,
indicate that the lack of reactivity against citrullinated MBP
peptides was not a technical problem. The observation that
some wells were only positive when testing for IFN-γ, is likely
explained by the fact that individual functions of T cells require
different strengths of stimulation (42). Modified/citrullinated
peptides may be less potent ligands compared to native peptides
and, since only one antigen concentration was tested, it is possible
that responsiveness was only observed for one functional readout
instead of both (42).
Since we did not examine antibody reactivity against
citrullinated proteins, the possibility remains that humoral
responses could still play a role in MS as is the case in RA (42).
Bodil et al. did not find elevated levels of antibodies either against
citrullinated proteins or PAD in MS patients (43). Furthermore,
decreased reactivity against citrullinated MBP was found in
serum and CSF of MS patients. However, this study examined
only two citrullinated MBP peptides (44).
Besides myelin proteins, we also identified additional
citrullinated sites in vimentin and CN37 from WMMS, whereas
numbers of CN37 and DPYL2 citrullinated peptides were slightly
increased in GMC tissue (Figure 4C). Some of the newly
identified citrullinated proteins like ermin (juxtanodin) and
DPYL2 (crmp-2) are of particular interest. Little is known about
ermin. It appears to be expressed only by oligodendrocytes and
involved in the compaction of myelin (45) and the formation
of axonal microtubules (46). It is interesting to note that
citrullinated ermin is present in tissue were compaction of
myelin is lost. Moscarello et al. were the first to hypothesize that
damage of white matter in MS results from a failure to maintain
compact myelin sheaths due to an increased citrullination of
MBP (47). Citrullination of ermin may occur as “collateral
damage.” MBP like ermin belongs to a group of proteins, which
are characterized as “intrinsically disordered proteins” that adopt
tertiary structure depending on the molecular environment (48).
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DPYL2 or (CRMP2) is a protein, which has been linked to
neurodegenerative disorders (49) and shown to be involved in
synaptic function. It appears in an interactome with proteins
involved in B cell differentiation (49) and in T cells in the
context of neuroinflammation in an animal model (50). Further,
it has been shown to have multiple PTMs and potentially many
interactors, among them structural proteins as tubulin (51).
Our list of citrullinated proteins shows a large number
of molecules involved in cytoskeleton formation, especially
vimentin, GFAP, tubulin and actin. The picture we obtained
from our MS tissues indicates that structural proteins are the
main targets of this particular post-translational modification.
Citrullination is considered to result from insult and damage,
leading to molecular and cellular breakdown. In addition,
recent publications show that post-translational modifications as
citrullination and deamidation also occur in the aging brain (32,
34, 36). Therefore, it is possible that the citrullination patterns
we obtained from control brain reflect the natural aging of brain
tissue. Nevertheless, citrullination occurred with a much higher
frequency in MS tissue as compared to control. This could be
due to inflammation, even if tissue is not overtly inflamed and
considered “normal-appearing,” and support the argument that
citrullination is not an initiator of the disease but the result.
Other PTM, such as phosphorylation occur also on MBP, but
their possible influence on disease course is currently not clear.
In summary, our study provides a comprehensive analysis
of citrullinated peptides in white- and gray matter of MS
patients and controls. We combined efficient protein extraction-
and separation techniques to analyze very small samples.
Thorough data mining with the support of complementary
software allowed us to establish a map of citrullinated
peptides and proteins. This proteomic approach in principle
provides the basis for multiple other studies on the role of
citrullination in MS brain tissue, but more broadly also with
respect to analyzing other post-translational modifications in
small tissue samples and identifying potential neo-antigens.
This information, i.e., whether structural proteins and or
those involved in inflammatory processes are citrullinated,
should improve the understanding whether citrullination is
implicated in distinct pathomechanisms in MS. Altered myelin,
either via structural alterations, during the processes of
de- and remyelination, neuronal/axonal loss or autoimmune
inflammation could result in neoantigens and thereby induce an
autoimmune reaction or increase demyelination (5).
The immunological testing in the present study focussed
on citrullinated MBP epitopes based on previous reports, and,
even though we examined CSF-infiltrating CD4+ T cells, we
did not find a marked response, which argues against a major
pathogenetic involvement of autoimmune T cells directed against
citrullinated MBP epitopes in MS.
AUTHOR CONTRIBUTIONS
WF designed and performed brain tissue experiments and
wrote the manuscript. CC performed all the cellular assays
and participated in writing the manuscript. WW performed
data extraction and bioinformatics analysis, and contributed to
discussions and writing of the manuscript. BR ran the mass
spectrometers and contributed to the progress in experimental
setups. PT-O and CS-M helped with CD4+ T cell expansion.
TZ performed immunohistochemistry and excision of brain
tissue samples. MP analyzed MRI images and clinical data. IJ
helped with analyzing the data and revised the manuscript.
NS-W provided the characterized brain tissue samples. MS
and RM were responsible for designing the questions of
the study, acquisition of grants, and contributed to writing
the manuscript.
FUNDING
The project was supported by the Clinical Research Priority
Program Multiple Sclerosis CRPPMS of the University of Zürich,
the European Research Council (ERC; ERC-2013-ADG 340733),
the Swiss National Science Foundation Sinergia grant Unmet-MS
(grant number CRSII3_54483) and Highly Specialized Medicine
II (HSMII) Targeted and interdisciplinary treatment of severe
immune-mediated diseases.
ACKNOWLEDGMENTS
We thank Richard Reynolds and the UK MS Tissue Bank for
the brain tissue. We acknowledge the histology laboratory at
the Department of Neuropathology, University Hospital Zürich
for their support, Christian Kempf for initial brain storming,
Tiannan Guo for introduction to PCT.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.00540/full#supplementary-material
Figure S1 | FDR (vertical axis) vs. score (horizontal axis). Green line FDR for
deamidated and citrullinated peptides. Yellow line. FDR for all the other peptides.
Figure S2 | Schematic picture of peptide fractionation and tissue
sampling on HILIC.
Supplementary Table 1 | Patient information: List of all patient tissues used in
the study including tissue block numbers for proteomics studies.
Supplementary Table 2 | List of peptides and quantification in control and MS
brain tissues. The table includes the complete list of peptides used in the assays
and the number of equivalent tryptic peptides found in the brain tissues of controls
(C) and MS cases using LC-mass spectrometry (LC-MS) technique.
Supplementary Table 3 | Extended clinical, including demographic and
HLA-DRB1 haplotypes of MS patients. Gender, age, disease duration at LP,
interval between last relapse and LP (Last relapse-LP delay), presence of ongoing
clinical relapse (Clinically Active), the delay between MRI and LP (MRI-LP delay),
presence of gadolinium-enhancing lesion at T1-MRI sequence (Radiologically
active), IgG index, IgGOB Pattern, IgM Index, IgA index, and CSF cells count (/uL)
and HLA-DRB1 typing are reported for each individual. CIS, clinical isolated
syndrome; RRMS, relapsing remitting MS; OCB, oligoclonal bands.
Supplementary Data 1 | All peptides identified with Mascot and Ursgal. PSM of
each peptides with reference to search engines used and their tissue distribution.
Frontiers in Immunology | www.frontiersin.org 15 April 2019 | Volume 10 | Article 540
Faigle et al. Brain Citrullination in Multiple Sclerosis
REFERENCES
1. Hensen SMM, Pruijn GJM. Methods for the detection of peptidylarginine
deiminase (PAD) activity and protein citrullination. Mol Cell Proteomics.
(2014) 13:388–96. doi: 10.1074/mcp.R113.033746
2. György B, Tóth E, Tarcsa E, Falus A, Buzás EI. Citrullination: a
posttranslational modification in health and disease. Int J Biochem Cell Biol.
(2006) 38:1662–77. doi: 10.1016/j.biocel.2006.03.008
3. Gudmann NS, Hansen NUB, Jensen ACB, Karsdal MA, Siebuhr AS. Biological
relevance of citrullinations: diagnostic, prognostic and therapeutic options.
Autoimmunity. (2015) 48:73–9. doi: 10.3109/08916934.2014.962024
4. Tarcsa E, Marekov LN, Mei G, Melino G, Lee S-C, Steinert PM. Protein
unfolding by peptidylarginine deiminase Substrate specificity and structural
relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem.
(1996) 271:30709–16.
5. Cao L, Goodin R, Wood D, Moscarello MA, Whitaker JN. Rapid
release and unusual stability of immunodominant peptide 45–89 from
citrullinated myelin basic protein. Biochemistry (Mosc). (1999) 38:6157–63.
doi: 10.1021/bi982960s
6. Catrina AI, Ytterberg AJ, Reynisdottir G, Malmström V, Klareskog L. Lungs,
joints and immunity against citrullinated proteins in rheumatoid arthritis.Nat
Rev Rheumatol. (2014) 10:645–53. doi: 10.1038/nrrheum.2014.115
7. GS Chirivi R. Citrullination: a target for disease intervention in multiple
sclerosis and other inflammatory diseases? J Clin Cell Immunol. (2013) 4:146.
doi: 10.4172/2155-9899.1000146
8. Pieper J, Dubnovitsky A, Gerstner C, James EA, Rieck M, Kozhukh
G, et al. Memory T cells specific to citrullinated α-enolase are
enriched in the rheumatic joint. J Autoimmun. (2018) 92:47–56.
doi: 10.1016/j.jaut.2018.04.004
9. Moscarello MA, Mastronardi FG, Wood DD. The role of citrullinated
proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis.
Neurochem Res. (2006) 32:251–6. doi: 10.1007/s11064-006-9144-5
10. Bradford CM, Ramos I, Cross AK, Haddock G, McQuaid S, Nicholas AP, et al.
Localisation of citrullinated proteins in normal appearing white matter and
lesions in the central nervous system in multiple sclerosis. J Neuroimmunol.
(2014) 273:85–95. doi: 10.1016/j.jneuroim.2014.05.007
11. Nicholas AP, Sambandam T, Echols JD, Tourtellotte WW. Increased
citrullinated glial fibrillary acidic protein in secondary progressive multiple
sclerosis. J Comp Neurol. (2004) 473:128–36. doi: 10.1002/cne.20102/abstract
12. SospedraM,Martin R. Immunology of multiple sclerosis.Annu Rev Immunol.
(2005) 23:683–747. doi: 10.1146/annurev.immunol.23.021704.115707
13. Martin R, Whitaker JN, Rhame L, Goodin RR, McFarland HF. Citrulline-
containing myelin basic protein is recognized by T-cell lines derived from
multiple sclerosis patients and healthy individuals. Neurology. (1994) 44:123.
14. Apostolopoulos V, Deraos G, Matsoukas M-T, Day S, Stojanovska L, Tselios
T, et al. Cyclic citrullinated MBP87–99 peptide stimulates T cell responses:
implications in triggering disease. Bioorg Med Chem. (2016) 25:528–38.
doi: 10.1016/j.bmc.2016.11.029
15. Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, et al. Memory B cells
activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell.
(2018) 175:85–100.e23. doi: 10.1016/j.cell.2018.08.011
16. Planas R, Santos R, Tomas-Ojer P, Cruciani C, Lutterotti A, Faigle
W, et al. GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen
in DRB3∗02:02 patients with multiple sclerosis. Sci Transl Med. (2018)
10:eaat4301. doi: 10.1126/scitranslmed.aat4301
17. Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch HM,
et al. Increased citrullination of histone H3 in multiple sclerosis brain and
animal models of demyelination: a role for tumor necrosis factor-induced
peptidylarginine deiminase 4 translocation. J Neurosci. (2006) 26:11387–96.
doi: 10.1523/JNEUROSCI.3349-06.2006
18. Erne B, Sansano S, Frank M, Schaeren-Wiemers N. Rafts in adult peripheral
nerve myelin contain major structural myelin proteins and myelin and
lymphocyte protein (MAL) and CD59 as specific markers. J Neurochem.
(2002) 82:550–62. doi: 10.1046/j.1471-4159.2002.00987.x/full
19. Guo T, Kouvonen P, Koh CC, Gillet LC, Wolski WE, Röst HL, et al.
Rapid mass spectrometric conversion of tissue biopsy samples into
permanent quantitative digital proteome maps. Nat Med. (2015) 21:407–13.
doi: 10.1038/nm.3807
20. Barkow-Oesterreicher S, Türker C, Panse C. FCC – an automated rule-based
processing tool for life science data. Source Code Biol Med. (2013) 8:1–7.
doi: 10.1186/1751-0473-8-3
21. Kremer LPM, Leufken J, Oyunchimeg P, Schulze S, Fufezan C. Ursgal,
universal python module combining common bottom-up proteomics
tools for large-scale analysis. J Proteome Res. (2016) 15:788–94.
doi: 10.1021/acs.jproteome.5b00860
22. Käll L, Storey JD, MacCoss MJ, Noble WS. Assigning significance to peptides
identified by tandem mass spectrometry using decoy databases. J Proteome
Res. (2008) 7:29–34. doi: 10.1021/pr700600n
23. Vizcaíno JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016
update of the PRIDE database and its related tools. Nucleic Acids Res. (2016)
44:D447–56. doi: 10.1093/nar/gkv1145
24. Szklarczyk D, Franceschini A,Wyder S, Forslund K, Heller D, Huerta-Cepas J,
et al. STRING v10: protein–protein interaction networks, integrated over the
tree of life. Nucleic Acids Res. (2015) 43:D447–52. doi: 10.1093/nar/gku1003
25. Ishigami A, Ohsawa T, Hiratsuka M, Taguchi H, Kobayashi S,
Saito Y, et al. Abnormal accumulation of citrullinated proteins
catalyzed by peptidylarginine deiminase in hippocampal extracts from
patients with Alzheimer’s disease. J Neurosci Res. (2005) 80:120–8.
doi: 10.1002/jnr.20431/abstract
26. Muraro PA, Kalbus M, Afshar G, McFarland HF, Martin R. T cell
response to 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase)
in multiple sclerosis patients. J Neuroimmunol. (2002) 130:233–42.
doi: 10.1016/S0165-5728(02)00229-1
27. MoscarelloMA, Lei H,Mastronardi FG,Winer S, Tsui H, Li Z, et al. Inhibition
of peptidyl-arginine deiminases reverses protein-hypercitrullination and
disease in mouse models of multiple sclerosis. Dis Model Mech. (2013)
6:467–78. doi: 10.1242/dmm.010520
28. Lee C-Y, Wang D, Wilhelm M, Zolg DP, Schmidt T, Schnatbaum K, et al.
Mining the human tissue proteome for protein citrullination. Mol Cell
Proteomics. (2018) 17:1378–91. doi: 10.1074/mcp.RA118.000696
29. Arimura N, Menager C, Fukata Y, Kaibuchi K. Role of CRMP-2 in neuronal
polarity. J Neurobiol. (2004) 58:34–47. doi: 10.1002/neu.10269
30. Brockschnieder D. Ermin, a myelinating oligodendrocyte-specific
protein that regulates cell morphology. J Neurosci. (2006) 26:757–62.
doi: 10.1523/JNEUROSCI.4317-05.2006
31. Kim JK, Mastronardi FG, Wood DD, Lubman DM, Zand R, Moscarello MA.
Multiple sclerosis an important role for post-translational modifications of
myelin basic protein in pathogenesis. Mol Cell Proteomics. (2003) 2:453–62.
doi: 10.1074/mcp.M200050-MCP200
32. Sarg B, Faserl K, Lindner HH. Identification of novel site-specific alterations
in the modification level of myelin basic protein isolated from mouse brain at
different ages using capillary electrophoresis–mass spectrometry. Proteomics.
(2017) 17:1700269. doi: 10.1002/pmic.201700269
33. Opdenakker G, Proost P, Van Damme J. Microbiomic and posttranslational
modifications as preludes to autoimmune diseases. Trends Mol Med. (2016)
22:746–57. doi: 10.1016/j.molmed.2016.07.002
34. Friedrich MG, Hancock SE, Raftery MJ, Truscott RJW. Isoaspartic acid
is present at specific sites in myelin basic protein from multiple sclerosis
patients: could this represent a trigger for disease onset? Acta Neuropathol
Commun. (2016) 4:83. doi: 10.1186/s40478-016-0348-x
35. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin
R. Expansion and functional relevance of high-avidity myelin-specific
CD4+ T cells in multiple sclerosis. J Immunol. (2004) 172:3893–904.
doi: 10.4049/jimmunol.172.6.3893
36. Gallart-Palau X, Lee BST, Adav SS, Qian J, Serra A, Park JE, et al. Gender
differences in white matter pathology and mitochondrial dysfunction in
Alzheimer’s disease with cerebrovascular disease. Mol Brain. (2016) 9:27.
doi: 10.1186/s13041-016-0205-7
37. Lutterotti A, Yousef S, Sputtek A, Sturner KH, Stellmann J-P, Breiden P,
et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells:
a phase 1 trial in multiple sclerosis. Sci Transl Med. (2013) 5:188ra75.
doi: 10.1126/scitranslmed.3006168
38. Nomura K. Specificity andmode of action of themuscle-type protein-arginine
deiminase. Arch Biochem Biophys. (1992) 293:362–9.
39. Hao G, Wang D, Gu J, Shen Q, Gross SS, Wang Y. Neutral loss of isocyanic
acid in peptide CID spectra: a novel diagnostic marker for mass spectrometric
Frontiers in Immunology | www.frontiersin.org 16 April 2019 | Volume 10 | Article 540
Faigle et al. Brain Citrullination in Multiple Sclerosis
identification of protein citrullination. J Am Soc Mass Spectrom. (2009)
20:723–7. doi: 10.1016/j.jasms.2008.12.012
40. Tranquill LR, Cao L, Ling NC, Kalbacher H, Martin RM, Whitaker
JN. Enhanced T cell responsiveness to citrulline-containing myelin
basic protein in multiple sclerosis patients. Mult Scler. (2000) 6:220–5.
doi: 10.1177/135245850000600402
41. Ge C, Xu B, Liang B, Lönnblom E, Lundström SL, Zubarev RA, et al.
Structural basis of cross-reactivity of anti-citrullinated protein antibodies.
Arthritis Rheumatol. (2018) 71:210–21. doi: 10.1002/art.40698
42. Hemmer B, Stefanova I, Vergelli M, Germain RN, Martin R. Relationships
among TCR ligand potency, thresholds for effector function elicitation,
and the quality of early signaling events in human T cells. J Immunol.
(1998) 160:5807–14.
43. Bodil Roth E, Theander E, Londos E, Sandberg-Wollheim M, Larsson Å,
Sjöberg K, et al. Pathogenesis of autoimmune diseases: antibodies against
transglutaminase, peptidylarginine deiminase and protein-bound citrulline in
primary Sjögren’s syndrome, multiple sclerosis and Alzheimer’s disease. Scand
J Immunol. (2008) 67:626–31. doi: 10.1111/j.1365-3083.2008.02115.x
44. de Seze J, Dubucquoi S, Lefranc D, Virecoulon F, Nuez I, Dutoit V, et al.
IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. J
Neuroimmunol. (2001) 117:149–55. doi: 10.1016/S0165-5728(01)00312-5
45. Liang F, Hwang JH, Tang NW, Hunziker W. Juxtanodin in retinal
pigment epithelial cells: expression and biological activities in regulating cell
morphology and actin cytoskeleton organization: LIANG et al. J CompNeurol.
(2018) 526:205–15. doi: 10.1002/cne.24301
46. Niwa S, Nakamura F, Tomabechi Y, Aoki M, Shigematsu H, Matsumoto T,
et al. Structural basis for CRMP2-induced axonal microtubule formation. Sci
Rep. (2017) 7:10681. doi: 10.1038/s41598-017-11031-4
47. Moscarello MA, Wood DD, Ackerley C, Boulias C. Myelin in multiple
sclerosis is developmentally immature. J Clin Invest. (1994) 94:146–54.
48. Ruskamo S, Chukhlieb M, Vahokoski J, Bhargav SP, Liang F, Kursula I, et al.
Juxtanodin is an intrinsically disordered F-actin-binding protein. Sci Rep.
(2012) 2:899. doi: 10.1038/srep00899
49. Martins-de-Souza D, Cassoli JS, Nascimento JM, Hensley K, Guest
PC, Pinzon-Velasco AM, et al. The protein interactome of collapsin
response mediator protein-2 (CRMP2/DPYSL2) reveals novel partner
proteins in brain tissue. Proteomics Clin Appl. (2015) 9:817–31.
doi: 10.1002/prca.201500004/full
50. Vuaillat C, Varrin-Doyer M, Bernard A, Sagardoy I, Cavagna S,
Chounlamountri I, et al. High CRMP2 expression in peripheral T
lymphocytes is associated with recruitment to the brain during virus-
induced neuroinflammation. J Neuroimmunol. (2008) 193:38–51.
doi: 10.1016/j.jneuroim.2007.09.033
51. Myllykoski M, Baumann A, Hensley K, Kursula P. Collapsin response
mediator protein 2: high-resolution crystal structure sheds light on small-
molecule binding, post-translational modifications, and conformational
flexibility. Amino Acids. (2017) 49:747–59. doi: 10.1007/s00726-016-
2376-z
Conflict of Interest Statement: MP reports grants and personal fees from
Novartis, Almirall, Biogen Idec, Sanofi Genzyme, and Teva outside the submitted
work. He served as advisory board member of Novartis, Biogen, and Sanofi
Genzyme.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Faigle, Cruciani, Wolski, Roschitzki, Puthenparampil, Tomas-
Ojer, Sellés-Moreno, Zeis, Jelcic, Schaeren-Wiemers, Sospedra and Martin. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Immunology | www.frontiersin.org 17 April 2019 | Volume 10 | Article 540
